Message from @Citizen Z
Discord ID: 637492217765822474
The Dynecorp/Dyneport vaccine connection.
https://steemit.com/pedogate/@v4vapid/dyncorp-vaccinations-and-me
```The United States biological weapons program began in 1943 and has been terminated in 1969. It is replaced by the United States biological defense program.
```
Military.pdf
holy crap... Noooooooo waaay Baaaby
Eww
maximilian432#4762 Stop spamming! This is warning number 2
@everyone
The “coronavirus” That is sweeping the headlines.
There was a patent for the coronavirus was filed in 2015 and granted in 2018.
Chocker right !"
https://patents.justia.com/patent/10130701
The state-of-the-art manufacturing facility is one of the first and largest green-field pharmaceutical projects by a Chinese company in Ireland. It will feature single-use bioreactors for commercial bio-manufacturing and be equipped with next-generation processing technology.
“The facility will enable WuXi to expand its commercial manufacturing capacities and strengthen its global integrated solution platform.”
The facility will be installed with 48,000l fed-batch bioreactors and 6,000l perfusion bioreactors. It will be one of the world’s largest facilities equipped with disposable bioreactors.
WuXi Biologics will work with local partners to build the new facility.
Financing for WuXi Biologics
The project is supported by the Irish Government through the IDA and Ireland Strategic Investment Fund (ISIF), a sovereign development fund managed by National Treasury - It will also help towards the Irish Government’s goal of increasing investment and jobs in the region by more than 40% under the Regional Action Plans for Jobs initiative.
Marketing commentary on WuXi Biologics - Wuxi Biologics is an affiliate of WuXi AppTec that offers biologics platforms for the discovery and development of biologics from concept to commercial manufacturing to clients worldwide. Along with the parent company, it provides a single source contract development solution to clients globally. The company’s three facilities in Wuxi city, Shanghai and Suzhou offer an open-access technology platform for the commercialisation of biologic drugs. WuXi also opened a bio-manufacturing facility in Philadelphia in 2015.
In addition to the Dundalk facility, WuXi is developing a new research and development (R&D) centre in Shanghai, China, through its subsidiary WuXi STA.
https://cdn.discordapp.com/attachments/549329993138831372/672429749074788352/US10130701_Patent.pdf
Pattented by British scientists August 2017 to November 2018 !!